KDC-MN-328 – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

URB597 is the standard research tool for blocking the FAAH enzyme that breaks down anandamide. Developed by Daniele Piomelli’s group at UC Irvine, it permanently inactivates FAAH by latching onto the active site, which raises endogenous anandamide for hours without giving cannabinoids directly. In animal studies it produces anxiolytic and analgesic effects without the cognitive impairment or reward signal that comes with direct CB1 activation, suggesting that elevated endocannabinoid tone might be therapeutically useful. The compound itself never reached human trials, but it laid the conceptual groundwork for clinical FAAH inhibitors like PF-04457845. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

55/100

Canonical FAAH probe with strong bench utility but murky translational story after Phase 2 MDD failure

Look, if you work in endocannabinoid biology, URB597 is probably already sitting on your shelf. Piomelli’s group at UC Irvine gave the field a genuinely clean probe: a covalent carbamate that carbamoylates the active-site serine of FAAH, producing irreversible inhibition with real selectivity over MAGL and other lipid hydrolases. That mechanism is what we like most about this compound. You’re not agonizing CB1 directly; you’re elevating endogenous anandamide and the other N-acylethanolamines and letting the system respond on its own terms. The pharmacological consequence is real and distinguishable from THC-like full agonism: anxiolytic and analgesic signal without the catalepsy, hypothermia, or intoxication that makes direct CB1 agonists so hard to work with in behavioral models.

The selectivity story holds up across labs. Multiple groups have used URB597 to dissect FAAH’s role in pain processing, fear extinction, and stress-induced analgesia, and the results have replicated reasonably well. The FAAH inhibition literature is one of the more coherent bodies of work to come out of the eCB field, and URB597 is at the center of it. If you’re running a FAAH knockout against a pharmacological model, URB597 is your positive control. There isnt a cleaner option for acute pharmacological FAAH inhibition in preclinical work right now.

Here’s the thing, though. The Phase 2 clinical trial in major depressive disorder didn’t pan out. No efficacy signal worth advancing to Phase 3. That failure doesnt invalidate the probe, and it doesn’t mean FAAH inhibition is biologically inert in humans, but it does mean the translational story is murky. The anxiolytic preclinical data hasn’t cleanly mapped to any approved indication. Pain is still an open question. The newer selective FAAH inhibitors like PF-04457845 showed early promise in pain work and also stalled. The BIA 10-2474 safety disaster in France in 2016 cast a shadow over the whole class even though URB597’s own selectivity profile looks meaningfully better. That shadow hasn’t fully lifted from the field’s reputation.

What does this mean for the research score? We think URB597 earns its place as a bench tool. It’s the reference probe for a still-active area of neuropharmacology. The endocannabinoid tone hypothesis isn’t dead; it’s waiting on better target engagement biomarkers and possibly a different indication space. The compound has enough replicated literature behind it that you know exactly what you’re getting. We don’t think it’s a priority new research direction, though. The novelty is gone, the clinical signal is weak, and the field has been trying to translate FAAH inhibition for over a decade with limited success. As a probe for answering specific mechanistic questions about eCB tone: yes, absolutely. As an exciting frontier research target in its own right: no. That’s a 55.

Novelty: 38
Mechanism promise: 60
In-category differentiation: 65
Evidence quality: 58
Translational signal: 40
Research bench value: 75

Rationale URB597 scores high on bench value as the definitive reference FAAH inhibitor in endocannabinoid research, but failed Phase 2 MDD trials and a decade of limited clinical translation drag the overall down hard. It earns its place in any serious eCB research program as a probe, not as a frontier therapeutic lead.

Selective FAAH inhibitor (research)

A carbamate inhibitor of fatty acid amide hydrolase (FAAH); the canonical research probe for elevating endogenous anandamide.

Abstract

URB597 (KDS-4103, cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester; CAS 546141-08-6; molecular formula C20H22N2O3; molecular weight 338.40) is a covalent carbamate inhibitor of fatty acid amide hydrolase (FAAH) developed by Piomelli and colleagues at UC Irvine. The compound carbamoylates the active-site serine of FAAH, producing irreversible enzyme inactivation. Selective for FAAH over MAGL and other lipases. Pharmacological consequence: elevation of endogenous anandamide and other N-acylethanolamides without direct CB receptor agonism. The behavioral profile differs from direct CB1 agonists like THC: anxiolytic and analgesic effects without the catalepsy, hypothermia, and intoxication characteristic of CB1 full agonism. Phase 2 clinical trials in major depressive disorder did not demonstrate efficacy; the compound did not advance to phase 3. Plasma half-life is approximately 6 hours; the irreversible mechanism produces effective FAAH inhibition for 24-48 hours after a single dose. Used as the canonical FAAH inhibitor in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-328Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-328

URB597

Abstract

Read the full monograph